The portfolio maintains a cost advantage over competitors, priced within the second-cheapest fee quintile among peers.
Virtus LifeSci Biotech Products ETF BBP
Morningstar’s Analysis BBP
Will BBP outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 27.4
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Tarsus Pharmaceuticals Inc Ordinary Shares | 3.66 | 671,773 | Healthcare |
ADMA Biologics Inc | 3.36 | 616,800 | Healthcare |
Agios Pharmaceuticals Inc | 2.84 | 521,525 | Healthcare |
SpringWorks Therapeutics Inc Ordinary Shares | 2.63 | 483,428 | Healthcare |
Moderna Inc | 2.61 | 478,708 | Healthcare |
Sarepta Therapeutics Inc | 2.57 | 472,111 | Healthcare |
Lexicon Pharmaceuticals Inc | 2.57 | 471,878 | Healthcare |
Ascendis Pharma A/S ADR | 2.50 | 459,401 | Healthcare |
Neurocrine Biosciences Inc | 2.40 | 439,883 | Healthcare |
Intra-Cellular Therapies Inc | 2.35 | 431,700 | Healthcare |